Literature DB >> 29421414

How to Treat a Patient with Thromboangiitis Obliterans: A Systematic Review.

Bahare Fazeli1, Maliheh Dadgar Moghadam2, Shabnam Niroumand3.   

Abstract

To date, there is still no treatment protocol for patients with thromboangiitis obliterans (TAO) who are also afflicted with critical limb ischemia (CLI). Smoking cessation on its own cannot be considered a treatment for the purposes of salvaging a limb of a TAO patient with CLI. The aim of this review was to evaluate different studies of various treatment protocols for avoiding amputation in TAO patients. A systematic search for relevant studies dating from 1990 to the end of 2016 was performed on the PubMed, SCOPUS, and Science Direct databases. Only 24 studies fulfilled the inclusion criteria, of which only one was a randomized controlled trial (RCT). The remaining studies were quasi-experimental with various treatments and follow-up durations. Therefore, meta-analysis was not performed. Judging from the major amputation rates after the suggested treatments were performed, no treatment was particularly effective. This review demonstrated that more standard RCTs are needed to resolve this treatment issue involved in TAO. In addition, because health insurance coverage for TAO patients differs by country, regional cost-benefit and cost-efficacy studies of the suggested treatments for TAO are highly recommended.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29421414     DOI: 10.1016/j.avsg.2017.10.022

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  11 in total

1.  Thromboangiitis Obliterans.

Authors:  Ju Yi Chen
Journal:  Anatol J Cardiol       Date:  2021-02       Impact factor: 1.596

2.  The Imbalance among Oxidative Biomarkers and Antioxidant Defense Systems in Thromboangiitis Obliterans (Winiwarter-Buerger Disease).

Authors:  Hiva Sharebiani; Bahare Fazeli; Rosanna Maniscalco; Daniela Ligi; Ferdinando Mannello
Journal:  J Clin Med       Date:  2020-04-07       Impact factor: 4.241

3.  Thromboangiitis Obliterans: 110 Years Old and Little Progress Made.

Authors:  Jeffrey W Olin
Journal:  J Am Heart Assoc       Date:  2018-12-04       Impact factor: 5.501

4.  Visceral bed involvement in thromboangiitis obliterans: a systematic review.

Authors:  Faeze Fakour; Bahare Fazeli
Journal:  Vasc Health Risk Manag       Date:  2019-08-15

5.  Integration of traditional Chinese medicine and nibble debridement and dressing method reduces thrombosis and inflammatory response in the treatment of thromboangiitis obliterans.

Authors:  Jianhua Li; Jingfeng Zhong; Chunfa Huang; Jiewen Guo; Bingyu Wang
Journal:  Ann Transl Med       Date:  2021-09

6.  Phase IV postmarketing surveillance study shows continued efficacy and safety of Stempeucel in patients with critical limb ischemia due to Buerger's disease.

Authors:  Pawan Kumar Gupta; Santanu Dutta; Sanjay Kala; Muralikrishna Nekkanti; Sanjay C Desai; Subhendu S Mahapatra; Anita Dhar; Radhakrishnan Raju; Rajkumar M; Arunanshu Behera; Shivashankar P; N S Raviraja; Pachaiyappan Viswanathan; Mithun Chandrashekar; Charan Thej; Prasanth K V; Jijy Abraham; Hema Boggarapu; K Udaykumar
Journal:  Stem Cells Transl Med       Date:  2021-09-13       Impact factor: 6.940

7.  Angiogenesis induction in Buerger's disease: a disease management double-edged sword?

Authors:  Bahare Fazeli; Shayan Keramat; Ladan Assadi; Hossein Taheri
Journal:  Orphanet J Rare Dis       Date:  2019-08-05       Impact factor: 4.123

8.  Assessment of T helper 17-associated cytokines in thromboangiitis obliterans.

Authors:  Shayan Keramat; Mohammad Hadi Sadeghian; Mohammad Reza Keramati; Bahare Fazeli
Journal:  J Inflamm Res       Date:  2019-09-05

9.  [Intervention of Vascular Dysplasia Caused by Different Mechanisms - Anlotinib for Right Lung Squamous Cell Carcinoma Combined with Thromboangiitis Obliterans: A Case Report and Literature Review].

Authors:  Huijuan Hao; Min Zhang; Guoqing Zhang; Hui Zhu; Wuping Bao
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-01-20

Review 10.  Personalized Cell Therapy for Patients with Peripheral Arterial Diseases in the Context of Genetic Alterations: Artificial Intelligence-Based Responder and Non-Responder Prediction.

Authors:  Amankeldi A Salybekov; Markus Wolfien; Shuzo Kobayashi; Gustav Steinhoff; Takayuki Asahara
Journal:  Cells       Date:  2021-11-23       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.